Sign in or Register
  |  

Creative Biolabs has successfully developed SARS, MERS and other anti-viral antibodies in the past to assist scientific research. Facing the difficult COVID-19, Creative Biolabs actively invests in antibody development to assist researchers to better understand the characteristics of 2019-nCoV and drug development. Currently, Creative Biolabs is proud to offer an extensive line of research antibodies to support the study of SARS-CoV-2/COVID-19, several of which were validated using virus-infected cell lysates.

Explore the collections of SARS-CoV-2/COVID-19 antibodies >

Human CHRNA9 Peptide (IRIPSDL) (PEP-159532CQ)

This product is synthetic peptide that is derived from Human CHRNA9 (AA 99-105). This peptide sequence corresponds to amino acid residues: IRIPSDL.
Specificity
Human
Format
Lyophilized powder
Storage
Store at -20°C
Introduction
This gene is a member of the ligand-gated ionic channel family and nicotinic acetylcholine receptor gene superfamily. It encodes a plasma membrane protein that forms homo- or hetero-oligomeric divalent cation channels. This protein is involved in cochlea hair cell development and is also expressed in the outer hair cells (OHCs) of the adult cochlea.
Alternative Name
Cholinergic Receptor Nicotinic Alpha 9 Subunit; Cholinergic Receptor, Nicotinic, Alpha Polypeptide 9; Cholinergic Receptor, Nicotinic, Alpha 9 (Neuronal); Cholinergic Receptor, Nicotinic Alpha 9; NACHRA9; Acetylcholine Receptor, Neuronal Nicotinic, Alpha-9 Subunit; Neuronal Acetylcholine Receptor Protein, Alpha-9 Subunit; Acetylcholine Receptor, Nicotinic, Alpha 9 (Neuronal);
Entrez Gene ID
UniProt ID
Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Submit a review Submit a review and you will get a coupon.
0 reviews
Loading...

Please try the standard protocols which include: protocols, troubleshooting and guide.

Click here to view the protocols, troubleshooting and guide.

Cat PEP-159532CQ
Conjugates
Size
Price $
  ADD TO CART
Request bulk or custom quote
Second antibody and isotype control